Galapagos NV (LTS:0JXZ)

€ 25.37 -0.57 (-2.2%) Market Cap: 1.69 Bil Enterprise Value: -1.64 Bil PE Ratio: 8.16 PB Ratio: 0.59 GF Score: 54/100

Q3 2024 Galapagos NV Earnings Call Transcript
Oct 31, 2024

€24.9 (-6.18%)

Earnings
Half Year 2024 Galapagos NV Earnings Call Transcript
Aug 02, 2024

€23.85 (-5.06%)

Earnings
Q1 2024 Galapagos NV Earnings Call Transcript
May 03, 2024

€27.09 (-0.07%)

Earnings
Full Year 2023 Galapagos NV Earnings Call Transcript
Feb 23, 2024

€33.27 (-7.52%)

Earnings
Galapagos NV at ASH Meeting & Exposition Transcript
Dec 10, 2023
Q3 2023 Galapagos NV Earnings Call Transcript
Nov 03, 2023

€34.58 (+7.93%)

Earnings
Half Year 2023 Galapagos NV Earnings Call Transcript
Aug 04, 2023

€39.28 (+2.05%)

Earnings
Q1 2023 Galapagos NV Earnings Call Transcript
May 05, 2023

€38.5 (+5.45%)

Earnings
Full Year 2022 Galapagos NV Earnings Call Transcript
Feb 24, 2023

€35.62 (-2.72%)

Earnings
Galapagos NV at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Galapagos NV Q3 2022 Earnings Call and R&D Update Transcript
Nov 04, 2022

€43.18 (-7.01%)

Earnings
Half Year 2022 Galapagos NV Earnings Call Transcript
Aug 05, 2022

€53.23 (+2.13%)

Earnings
Galapagos NV to Acquire CellPoint BV and Abound Bio Inc M&A Call Transcript
Jun 22, 2022
Q1 2022 Galapagos NV Earnings Call Transcript
May 06, 2022

€57.16 (-0.71%)

Earnings
Q4 2021 Galapagos NV Earnings Call Transcript
Feb 25, 2022

€59.36 (+3.39%)

Earnings
Galapagos NV at JPMorgan Healthcare Conference Transcript
Jan 13, 2022
Q3 2021 Galapagos NV Earnings Call Transcript
Nov 05, 2021

€47.1 (-1.89%)

Earnings
Galapagos NV at Citi Biopharma Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Galapagos NV Earnings Call Transcript
Aug 06, 2021

€51.68 (+1.63%)

Earnings
Q1 2021 Galapagos NV Earnings Call Transcript
May 07, 2021

€63.04 (+1.29%)

Earnings
Q4 2020 Galapagos NV Earnings Call Transcript
Feb 19, 2021

€70.68 (+2.12%)

Earnings
Galapagos NV at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Galapagos NV & Gilead Sciences Inc to Announce New Commercialization and Development Agreement for Rheumatoid Arthritis Treatment Call Transcript
Dec 16, 2020
Q3 2020 Galapagos NV Earnings Call Transcript
Nov 06, 2020

€102.12 (-5.80%)

Earnings
Galapagos NV Inaugural Toledo Roundtable Presentation (Virtual) Transcript
Oct 27, 2020
H1 2020 Galapagos NV Earnings Call Transcript
Aug 07, 2020

€160.9 (+0.74%)

Earnings
Q1 2020 Galapagos NV Earnings Call Transcript
May 08, 2020

€210.05

Earnings
Q4 2019 Galapagos NV Earnings Call Transcript
Feb 21, 2020

€247.05 (+0.96%)

Earnings
Galapagos NV at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Galapagos NV R&D Update 2019 Transcript
Nov 14, 2019
Q3 2019 Galapagos NV Earnings Call Transcript
Oct 25, 2019

€147.63 (+2.02%)

Earnings
Q2 2019 Galapagos NV Earnings Call Transcript
Jul 26, 2019

€160.05 (+0.23%)

Earnings
Gilead Sciences Inc and Galapagos NV Enter Into Transformative Research and Development Collaboration Call Transcript
Jul 14, 2019
Q1 2019 Galapagos NV Earnings Call Transcript
Apr 26, 2019

€100.02 (-1.29%)

Earnings
Q4 2018 Galapagos NV Earnings Call Transcript
Feb 22, 2019

€85.78 (-3.00%)

Earnings

Galapagos NV Q3 2022 Earnings Call and R&D Update Transcript

Nov 04, 2022 / 12:00PM GMT

Release Date Price: €43.18 (-7.01%)

Transcript

Sofie Van Gijsel;Paul Stoffels

Galapagos NV - Head of IR;Galapagos NV - CEO, Chairman & Member of Management

Welcome all to the Galapagos Capital Markets Day and third quarter results. This presentation is webcast and accessible via the Galapagos website home page. The presentation will be available for download and replay later on today.

I would like to remind everyone that we will be making forward-looking statements during today's webcast. These forward-looking statements include remarks concerning future developments of the pipeline in our company and possible changes in the industry and competitive environments. Because these forward-looking statements involve risks and uncertainties, Galapagos' actual results may differ materially from the results expressed or implied in these statements.

We start today with our strategic and financial updates, followed by a deep dive in our efforts in oncology. Next, we discuss our immunology franchise and commercial capabilities, followed by Q&A. And with that, I'll now turn it over to Paul. Thank you.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.